Exclusive translation – Abdul Rahman Muhammad: The American company, Merck & Co., announced that its experimental drug to treat the emerging corona virus has reduced the rate of hospitalization patients by half.
Effective result in 5 days
The American company said that early results showed that patients who received the drug “molnopiravir” within five days of showing symptoms of the virus, had a reduced rate of hospitalizations and deaths by half.
According to the British newspaper, “Daily Mail”, researchers tracked 775 adults with mild to moderate COVID-19 who were more likely to be infected due to health problems.
real estate effect
Research found that only 7.3% were either hospitalized or died after 30 days had passed, compared to 14.1% of those who took molonopiravir, as the drug prevents viruses like the coronavirus from making copies of itself and spreading throughout the body.
It is noteworthy that Merck & Mo plans to present its drug, “molnopiravir” at a future medical meeting, and is seeking to apply for permission from the US Food and Drug Administration (FDA) as well as with authorities around the world to provide it.